WntResearch AB

Equities

WNT

SE0003553130

Biotechnology & Medical Research

End-of-day quote NORDIC GROWTH MARKET Other stock markets 06:00:00 2024-01-30 pm EST			5-day change	1st Jan Change
0.067 ^SEK	-.--%		-.--%	-27.17%

Feb. 29	WntResearch AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI
Feb. 29	WntResearch AB Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Resigning WntResearch CEO tells BioStock: "It will be exciting to follow!"

March 01, 2024 at 02:16 am EST

Upon writing her last CEO comment in the company's Q4 report, WntResearch's resigning CEO Pernilla Sandwall talks about a "transformative" 2023 for the company. Based on the company releasing new data, updating their NeoFox trial and aquiring a new CEO, the labelling seems appropriate. BioStock reached out to Sandwall for a comment.

Read the full article at biostock.se:

https://www.biostock.se/en/2024/03/resigning-ceo-on-the-future-of-wntresearch-it-will-be-exciting-to-follow/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

https://news.cision.com/wntresearch/r/resigning-wntresearch-ceo-tells-biostock---it-will-be-exciting-to-follow-,c3938871

Latest news about WntResearch AB

WntResearch AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29	CI
WntResearch AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
WntResearch Initiates Collaboration with Business Sweden with the Goal of Establishing Commercial Partnerships for Foxy-5 in Japan and South Korea	Feb. 26	CI
WntResearch AB Continues to the Next Step in the Phase 2 Study Neofox with the Highest Evaluated Dose of Foxy-5	Feb. 12	CI
WntResearch Announces CEO Changes	Jan. 09	CI
WntResearch Continues to the Second Dose Group in Clinical Proof of Concept Study of Foxy-5	Dec. 06	CI
WntResearch AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 16	CI
WntResearch AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-17	CI
Certain Shares of WntResearch AB are subject to a Lock-Up Agreement Ending on 16-JUL-2023.	23-07-15	CI
WntResearch AB Announces New Study Plan Approves for Wnt Research's Phase II Study	23-07-14	CI
WntResearch AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
WntResearch AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-09	CI
WntResearch AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-09	CI
WntResearch AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-17	CI
WntResearch AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-18	CI
WntResearch AB Announces Appointment of Pernilla Sandwall as the New CEO	22-06-27	CI
WntResearch AB Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-05	CI
WntResearch Announces Appointment of Pernilla Sandwall as CEO	22-02-13	CI
WntResearch AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2021	22-02-09	CI
WntResearch files a patent application for the treatment of Acute Myeloid Leukemia	21-12-13	CI
WntResearch AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-17	CI
WntResearch : to Look for New CEO as Acting Chief Steps Down	21-09-09	MT
Anders Rabbe Decides to Move on from Wntresearch AB	21-09-09	CI
WntResearch AB Announces Update on Patient Recruitment for the Ongoing Phase IIa Clinical Study Neofox with Wntresearch's Drug Candidate Foxy-5	21-04-14	CI
Wntresearch AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2020	21-02-08	CI

Chart WntResearch AB

Duration

Period

More charts

Company Profile

WntResearch AB is a Sweden-based company engaged in the translational cancer research. Its aim is to develop anti-metastatic therapies based on an increased understanding of the mechanisms underlying the metastatic process and the evaluation of specific small molecules that can specifically interact with this process. The Companyâs programs focus on the role of the Wnt-5a protein in the metastatic process. As of December 31, 2011, the Company had two projects, namely Foxy-5 and Box-5. Foxy-5 is a hexapeptide mimicking the effects of WNT-5a. Box-5 is a peptide antagonizing the effects of Wnt-5a. As of March 31, 2012, the Companyâs largest shareholder was Forskarpatent I Syd AB, which held 26.55% shares.

Sector

Biotechnology & Medical Research

Calendar

2024-05-02 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
WNTRESEARCH AB	-27.17%	5.32M
VERTEX PHARMACEUTICALS INCORPORATED	-1.65%	103B
REGENERON PHARMACEUTICALS, INC.	+6.75%	101B
ARGENX SE	+6.70%	23.07B
BIONTECH SE	-12.60%	22.23B
GENMAB A/S	-5.43%	18.05B
WUXI APPTEC CO., LTD.	-39.98%	17.18B
BEIGENE, LTD.	-10.17%	16.94B
NEUROCRINE BIOSCIENCES, INC.	+6.12%	14.07B
SAREPTA THERAPEUTICS, INC.	+35.47%	12.35B

Bio Therapeutic Drugs